Cannabis Weekly Round-Up: Peru on Path for Legal Medical Cannabis
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
Your trusted source for investing success
Your trusted source for investing success
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
What if the “one-size-fits-all” approach to medicine isn’t the right way treat medical conditions? Could a personalized medicine approach provide better treatment?
BioCryst Pharmaceuticals announced the FDA approved a supplemental new drug application for RAPIVAB.
By Shelly Kumar
Enertopia Corporation (CNSX:TOP; OTCQB:ENRT) is pleased to announce the second phase of bench testing for the recovery of Lithium and ultimately, upgrading the Lithium to battery grade Li2CO3 by our technology partner Genesis Water Technologies Inc., (GWT) a global leader in specialized water treatment solutions. The lithium processing technology testing is
By Shelly Kumar
Berkwood Resources Ltd. (TSXV:BKR) is pleased to announce that its Board of Directors (the “Board”) has adopted a shareholder rights plan (the “Plan”). The Plan is designed to promote equitable treatment of our shareholders in any public offer aimed at the purchase of the Company.
Tom Yingling, President and CEO states, “Berkwood Resources is well
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083).
DelMar’s new patent strengthens the Company’s control over
Elite Pharmaceuticals filed an abbreviated new drug application with the FDA for a generic version of OxyContin.
The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.
The Investing News Network (INN) takes a closer look at the top biotech companies listed on the NASDAQ so far this year, with a market cap between 50 and 500 million.
Revive Therapeutics announced it entered into a license agreement with South Carolina Research Foundation.
Medigus announced its financial results for the second quarter of 2017.
By Shelly Kumar
Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder.
“The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers
Nabriva Therapeutics plc saw its stock get a major boost on Monday morning after the company announced top-line results from their trial of a pneumonia drug.
Tetra Bio-Pharma announces that it will be filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients.
By Shelly Kumar
DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.
“The opening of this
CASI Pharmaceuticals, Savara, Adverum Biotechnologies, ChromaDex Therapeutics and MannKind top the NASDAQ biotech stock list.
Soleno Therapeutics presented new efficacy data from the pilot clinical trial of Diazoxide Choline Controlled-Release Tablet treating Prader-Willi syndrome at the International Meeting of Pediatric Endocrinology.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
Daxor announced it will be exhibiting at an upcoming heart medical conference.
The global stem cell therapy market is expected to grow at a CAGR of 36.52 percent between 2017 and 2021. Here are 10 top stem cell companies on the NASDAQ.
